When Is Hormone Therapy Really Worth It?


For Most Men With Prostate Cancer, Hormone Therapy With Postprostatectomy Radiotherapy Confers No Survival Benefit - The ASCO Post

New landmark research redraws the map on androgen deprivation therapy — who truly benefits, how long treatment should last, and what the very real side effects mean for your quality of life.

IPCSG Medical Education Staff  |  Sources: The Lancet, JAMA Oncology, ASCO GU 2026, NCI, ASCO, UCLA Health, University Hospitals Seidman Cancer Center, European Urology Oncology, Scientific Reports

Bottom Line Up Front (BLUF)

Androgen deprivation therapy (ADT) — hormone therapy that lowers testosterone — has long been a cornerstone of prostate cancer treatment, but three major new analyses published in early 2026 have clarified when it actually saves lives and when it may do more harm than good. For men receiving salvage radiation after prostatectomy, ADT appears to offer a meaningful survival benefit only if their pre-radiation PSA is above 0.5 ng/mL. For men with localized prostate cancer on definitive radiation, most of the cancer-fighting benefit of ADT occurs within the first 9–12 months — extending it longer provides diminishing returns while increasing risks of heart disease, metabolic problems, bone loss, and cognitive decline. The bottom line: hormone therapy is a powerful tool, but the emerging evidence strongly supports a personalized, risk-stratified approach rather than blanket, long-duration treatment for every patient.

The Big Picture: What ADT Does and Why It's Complicated

Androgen deprivation therapy works by dramatically lowering the levels of male hormones — primarily testosterone — that fuel prostate cancer growth. It can normalize PSA levels in over 90% of patients and shrink or slow tumors in 80–90% of cases. For men with advanced, metastatic, or recurrent prostate cancer, it remains an essential part of treatment.

But ADT is not a cure. Many cancers eventually develop resistance and continue growing despite low testosterone — a condition called castration-resistant prostate cancer (CRPC). And because testosterone plays a vital role in maintaining muscle and bone mass, heart health, metabolism, brain function, and sexual health, suppressing it for long periods comes with a steep price tag in quality of life.

For decades, oncologists debated who needs ADT, how much, and for how long. A wave of major new research in 2025–2026 has provided the clearest answers yet.

How ADT Works

Most ADT is delivered via injections of LHRH agonists (such as leuprolide/Lupron) or LHRH antagonists (such as degarelix/Firmagon) that suppress testosterone production by the testicles. It can also be combined with androgen receptor blockers such as enzalutamide (Xtandi), apalutamide (Erleada), or darolutamide (Nubeqa), or with androgen synthesis inhibitors such as abiraterone (Zytiga), which block testosterone production in the adrenal glands and tumor cells as well.

The POSEIDON Study: Rethinking ADT After Prostatectomy

One of the most important prostate cancer studies presented at the 2026 ASCO Genitourinary Cancers Symposium was the POSEIDON meta-analysis, published simultaneously in The Lancet on February 26, 2026. Led by Dr. Amar U. Kishan of UCLA, POSEIDON analyzed individual patient data from more than 6,000 men enrolled in six major randomized phase III trials. These were men who had experienced a PSA rise after prostatectomy and were receiving postoperative radiation therapy — a common and critical clinical scenario.

The core finding was striking: overall, adding hormone therapy to postoperative radiation did not produce a statistically significant improvement in survival across the entire patient population. The 10-year survival advantage amounted to just 0.7 percentage points (83.6% alive without ADT vs. 84.3% with it). That small absolute benefit led Dr. Kishan to emphasize: "More important than any hazard ratio is the absolute benefit, which was projected at 10 years to be only 0.7%."

"Who needs hormone therapy with postprostatectomy radiotherapy for a survival benefit? Patients with a PSA level of more than 0.5 ng/mL prior to radiation. How long does hormone therapy need to be? For most patients, short-term hormone therapy — 4 to 6 months — will suffice."

— Dr. Amar U. Kishan, UCLA, ASCO GU Symposium 2026

The PSA Threshold That Changes Everything

But POSEIDON was not a simple story of "ADT doesn't help." The researchers found that PSA level at the time radiation begins is a critical predictor of who benefits:

Men with a pre-radiation PSA of 0.5 ng/mL or less — the majority of men treated today, since most physicians pursue early salvage radiation — derived no meaningful overall survival or metastasis-free survival benefit from the addition of hormone therapy.

Men with higher PSA levels did see modest benefits. For those with PSA above 1.6 ng/mL, long-term hormone therapy (24 months) showed a significant survival advantage. The "number needed to treat" calculation is revealing: for a man with PSA ≤0.2 ng/mL, you would need to treat 125 men with ADT to prevent a single death — while for a man with PSA >1.0 ng/mL, only 25 men would need treatment to prevent one death.

Short-Term Is Enough for Most

POSEIDON also addressed a longstanding clinical debate: does longer ADT provide more benefit? The answer, for most patients in this setting, is no. The study found no significant advantage to 24-month (long-term) versus 4-to-6-month (short-term) hormone therapy for the overall population. Only men with PSA above 1.6 ng/mL appeared to gain additional benefit from extended treatment.

Key Findings — POSEIDON Meta-Analysis (Lancet, February 2026)
  • • 6,057 patients across 6 randomized phase III trials; median follow-up 9 years
  • • Overall 10-year survival: 83.6% (radiation alone) vs. 84.3% (radiation + ADT) — not statistically significant (p=0.06)
  • • No survival benefit from adding ADT for men with pre-radiation PSA ≤0.5 ng/mL
  • • Meaningful benefit for men with PSA >0.5 ng/mL; long-term ADT benefit clearest for PSA >1.6 ng/mL
  • • Short-term ADT (4–6 months) adequate for most patients; longer duration not consistently better
  • • PSMA-PET imaging and genomic classifiers (Decipher) were not available during these trials — these tools may further refine patient selection in the future

Discussant Dr. Bridget Koontz of AdventHealth Cancer Institute noted the results are "either practice-changing or practice-supporting, depending on how one currently practices." She emphasized that these findings apply specifically to men with PET-negative biochemical recurrence — men with PET-positive nodal or metastatic disease should still receive radiation and hormone therapy.

Dr. Neha Vapiwala, President of ASTRO and a radiation oncologist at the University of Pennsylvania, added an important nuance: "PSA alone does not typically dictate ADT decisions. These findings reinforce the value of personalizing treatment based on a broader clinical context," including factors like PSA doubling time, Gleason grade, pathologic staging, and genomic classifiers.

The JAMA Oncology Study: How Long Is Long Enough?

A second major analysis published in JAMA Oncology in January 2026 tackled a related but distinct question: for men with localized prostate cancer (not yet recurrent) receiving definitive radiation therapy, what is the ideal ADT duration?

Led by Dr. Nicholas Zaorsky of University Hospitals Seidman Cancer Center and the MARCAP Consortium, this meta-analysis pooled individual patient data from 13 randomized phase III trials covering 10,266 patients with median follow-up of more than 11 years.

The study found that ADT benefits follow a nonlinear curve: the cancer-fighting gains accelerate early and then plateau. Most of the benefit occurs within the first 9 to 12 months. Beyond that point, extending ADT provides only modest additional cancer control while the risks of death from other causes continue to increase in a near-linear fashion.

Optimal ADT Duration by Risk Group (JAMA Oncology, January 2026)

Favorable intermediate-risk (1 risk factor): 0 months — ADT often provides little benefit and may be omitted

Unfavorable intermediate-risk (2+ risk factors): ~6 months of ADT

High-risk disease: ~12 months of ADT

Very high-risk disease: Duration undefined — may require extended treatment; ongoing trials will clarify

A troubling finding: long-term ADT use was associated with a 28% increase in non-prostate-cancer mortality (heart disease, stroke, metabolic complications) for patients receiving 28 months versus no ADT. "Longer durations improve cancer outcomes, but the incremental benefit plateaus after approximately 9–12 months for high-risk patients," said senior author Dr. Daniel Spratt. "Beyond this point, additional ADT provides diminishing cancer control while continuing to increase the risk of non–prostate cancer death."

Dr. Spratt's team also noted a critically underappreciated issue: up to 50% of men prescribed long-term ADT in clinical trials stopped early due to poor tolerability — meaning real-world outcomes from extended ADT are likely worse than trial results suggest.

The UCLA Analysis: Most Benefit Happens in the First Year

A complementary study from UCLA Health, published in late 2025, further reinforced these findings using the MARCAP Consortium dataset of 10,266 men across 13 international clinical trials. This analysis found that most of the benefits of ADT occur within the first 9 to 12 months of treatment. Extending therapy beyond that provides only small additional cancer protection while substantially increasing the risk of cardiovascular, bone, and metabolic complications.

"Prostate cancer treatment should not be one-size-fits-all," said Dr. Kishan. "Physicians can now use patient-specific factors, including cancer risk, overall health, age and preferences, to make more informed decisions about ADT duration, improving both safety and quality of life."

The Real Costs of ADT: Side Effects You Need to Know

Understanding ADT's side effects is essential for every patient considering or currently on hormone therapy. These effects are not rare nuisances — they are common, significant, and in some cases permanent.

Physical Effects
  • Hot flashes (up to 80% of men)
  • Loss of libido and erectile dysfunction
  • Fatigue and loss of energy
  • Muscle loss and weight gain
  • Bone density loss (osteoporosis risk)
  • Gynecomastia (breast tissue growth)
  • Anemia
Metabolic & Cardiovascular Effects
  • Insulin resistance and diabetes
  • Elevated cholesterol and triglycerides
  • Increased cardiovascular disease risk
  • Increased risk of heart attack and stroke
  • Metabolic syndrome
  • Increased fracture risk
Cognitive & Emotional Effects
  • Memory and concentration problems
  • Mood changes and depression
  • Elevated dementia risk (see below)
  • Reduced brain white matter integrity
  • Fatigue-related cognitive slowing
Quality of Life
  • Significant declines in sexual function
  • Reduced physical capacity
  • Psychological impact on identity
  • Sleep disturbances
  • Relationship effects on partners

The Dementia Question

Perhaps the most alarming emerging concern is ADT's potential link to cognitive decline and dementia. The evidence is contested but accumulating.

A large-scale 2023 study using real-world data from more than 627,000 U.S. prostate cancer patients found that ADT use was associated with a 60% increased risk of dementia, with the highest risk seen with GnRH antagonists (a 92% increase). A 2025 meta-analysis of 17 cohort studies found a 20–26% higher dementia risk for men on ADT, rising to 40% for those on androgen receptor-targeted therapy or who underwent orchiectomy. It is estimated that 25–50% of men on ADT experience some degree of cognitive decline.

However, the picture is not entirely clear. A 2025 nationwide South Korean cohort study found no statistically significant increase in overall dementia risk with ADT, though it did find elevated Alzheimer's risk specifically. A large Swedish study found that men with high-risk prostate cancer treated with ADT had increased risks of both Alzheimer's disease (HR 1.37) and vascular dementia (HR 1.51), but men with low- or intermediate-risk disease had much smaller or no increased risk.

Important Caution

Because of these cognitive concerns, experts recommend that physicians assess cognitive status before starting ADT and monitor patients regularly during treatment. Men with pre-existing cognitive impairment or a family history of Alzheimer's may face a higher risk and should discuss this carefully with their medical team.

Managing ADT Side Effects: What the Evidence Supports

The good news is that many ADT side effects can be meaningfully reduced with proactive management:

Exercise is the single most evidence-supported intervention. Supervised exercise programs — both aerobic and resistance training — have been shown to significantly improve ADT-related fatigue, reduce cardiovascular risk, preserve muscle mass, and improve mental health. Studies consistently show that resistance training can build muscle mass even while on ADT.

Bone protection can be achieved with bisphosphonates or denosumab (Prolia/Xgeva). Denosumab has shown superior effectiveness compared to bisphosphonates in preventing skeletal complications.

Hot flashes affect up to 80% of men on ADT. While no treatment is perfect, gabapentin and certain antidepressants (like venlafaxine) have shown moderate benefit. Acupuncture may provide additional relief for some men.

Cardiovascular risk can be reduced through standard heart-healthy lifestyle modifications: regular exercise, diet, blood pressure management, and statin therapy where appropriate. The American Heart Association, American Cancer Society, and American Urological Association have issued a joint advisory on managing cardiovascular risk in men receiving ADT.

Intermittent ADT — cycling treatment on and off rather than using it continuously — may preserve quality of life for selected patients, particularly those experiencing biochemical recurrence. While it does not appear to improve cancer outcomes compared to continuous ADT, it is associated with fewer metabolic, bone, and sexual side effects during off-treatment periods.

So When Is ADT Clearly Beneficial?

Synthesizing the current evidence, ADT provides clear, meaningful survival benefit in these settings:

Metastatic hormone-sensitive prostate cancer (mHSPC): ADT combined with next-generation agents like enzalutamide, apalutamide, abiraterone, or docetaxel is the established standard of care and can add years to survival. This is where ADT's value is most unambiguous.

High-risk and very high-risk localized prostate cancer receiving radiation: ADT combined with definitive radiation significantly improves metastasis-free survival and overall survival. The benefit is real and robust. Duration should be approximately 12 months for high-risk disease, and extended (24+ months) may be appropriate for very high-risk cases.

Locally advanced (T3–T4) disease: ADT with radiation has demonstrated overall survival benefit in multiple large trials.

Salvage radiation after prostatectomy with PSA >0.5 ng/mL: Short-term ADT (4–6 months) adds meaningful benefit. For PSA >1.6 ng/mL, longer-term ADT may provide additional protection.

Non-metastatic castration-resistant prostate cancer (nmCRPC) with rapidly rising PSA: Second-generation anti-androgens like enzalutamide, apalutamide, or darolutamide added to ongoing ADT significantly delay metastasis and extend survival.

Where ADT Benefit Is Less Clear or Minimal

• Favorable intermediate-risk disease receiving radiation: Many men in this group may not benefit from ADT at all, according to the 2026 JAMA Oncology analysis.

• Salvage radiation after prostatectomy with PSA ≤0.5 ng/mL: POSEIDON found no meaningful survival benefit from adding ADT in this group, which represents most men receiving early salvage radiation today.

• Low-risk localized disease: ADT provides no established benefit when combined with primary treatment for low-risk prostate cancer.

• ADT as primary therapy without radiation or surgery in men with localized disease: Not recommended; ADT alone does not cure localized prostate cancer.

What's Coming: Smarter Patient Selection

All of the recent research acknowledges that the clinical trials underlying these analyses were conducted before two transformative tools became available: PSMA PET/CT imaging and genomic classifiers such as the Decipher test.

PSMA PET scans can now detect metastatic disease at PSA levels as low as 0.2 ng/mL — far below what older conventional scans could detect. A man with a rising PSA after surgery who would previously have been treated empirically with salvage radiation plus ADT may now be found to have a single lymph node metastasis that can be targeted precisely — potentially changing the entire treatment strategy.

Genomic classifiers like Decipher measure the biological aggressiveness of a tumor at the molecular level. Research is underway — particularly through the NRG-GU-006 (BALANCE) trial — to determine whether genomic tumor biology can predict which patients will benefit from adding ADT. "This is a space where data from biomarker-driven trials like BALANCE are going to be particularly helpful," said Dr. Kishan.

Questions to Ask Your Doctor About ADT

  1. Given my PSA level, pathology, and imaging results, do I fall into a group that clearly benefits from ADT?
  2. What is the absolute survival benefit of ADT for someone with my specific risk profile — not just the relative benefit?
  3. What is the recommended duration of ADT in my case, and is the evidence supporting long-term vs. short-term treatment in my specific situation?
  4. Do my existing health conditions (heart disease, diabetes, cognitive concerns) change the risk-benefit calculation?
  5. Would a PSMA PET scan or a genomic classifier like Decipher change the treatment recommendation?
  6. Can I discuss intermittent ADT as an option to preserve quality of life?
  7. What proactive steps (exercise program, bone protection, cardiovascular monitoring) should I take to minimize side effects?
  8. Who should I see — cardiologist, bone specialist, neurologist — for co-management during ADT?

The Bottom Line for IPCSG Members

Hormone therapy remains an irreplaceable tool in the fight against prostate cancer — but it is a tool that demands precision. The landmark POSEIDON, JAMA Oncology, and UCLA analyses of 2025–2026 collectively make the strongest case yet that more ADT is not always better, and that for many men — particularly those receiving early salvage radiation with low PSA values, or those with intermediate-risk localized disease — the burdens of hormone therapy may outweigh its benefits.

At the same time, for men with high-risk, locally advanced, or metastatic disease, ADT remains a life-extending treatment that should not be withheld.

The era of blanket, one-size-fits-all hormone therapy is giving way to a more nuanced, evidence-driven approach that weighs PSA level, tumor biology, overall health, cardiovascular risk, age, and patient preferences — together, collaboratively, between you and your medical team.

If you are currently on ADT or facing a decision about it, bring these studies to your next appointment. You deserve a conversation that goes beyond general guidelines to address your specific situation.

Verified Sources & Formal Citations

This article is prepared for educational purposes for members of the Informed Prostate Cancer Support Group (IPCSG). It is not a substitute for personalized medical advice. Always discuss treatment decisions with your oncologist and medical team. Information reflects research available as of March 2026.

IPCSG · San Diego, California · ipcsg.org

 

Comments

Post a Comment

Popular posts from this blog

Dr. Christopher Kane of UCSD Health Appointed Chairman of the American Board of Urology

Image
  Dr. Christopher Kane of UCSD Health Appointed Chairman of the American Board of Urology SAN DIEGO, May 21, 2025 - Dr. Christopher Kane, a distinguished urologist and Professor of Urology at UC San Diego Health, has been appointed Chairman of the American Board of Urology (ABU), the organization announced today. Dr. Kane, who has served as CEO of UC San Diego Health Physician Group and Dean of Clinical Affairs at the UC San Diego School of Medicine, brings decades of experience in urologic oncology and leadership to this prestigious national position. Extensive Academic and Research Background Dr. Kane earned his medical degree from Uniformed Services University in Bethesda, Maryland, followed by a residency in urology at the Naval Medical Center San Diego and a fellowship in urologic oncology at the National Cancer Institute. He joined the UCSD faculty in 2007 after serving as a Navy physician for 12 years. As the C. Lowell and JoEllen Parsons Endowed Chair in Urology, Dr. ...
Read more

PSMA-Targeted Therapies for Prostate Cancer: Move Treatment Earlier in Disease Course

Image
  Interactive Graphic PSMA-Targeted Therapies for Prostate Cancer: Move Treatment Earlier in Disease Course Landmark FDA approval expands access to radioligand therapy while new research explores next-generation treatments By [Your Name] for the IPCSG Newsletter The landscape of prostate cancer treatment has undergone a seismic shift in recent months, with groundbreaking advances in prostate-specific membrane antigen (PSMA)-targeted therapies offering new hope to patients across different stages of the disease. Most significantly, the FDA's March 2025 expansion of Pluvicto (lutetium-177-PSMA-617) approval now allows treatment before chemotherapy, potentially tripling the number of eligible patients. Major FDA Approval Expands Treatment Access On March 28, 2025, the FDA approved a crucial expansion of Pluvicto's indication, allowing its use in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen recepto...
Read more

ASCO 2025: Non-Androgen-Receptor–Driven Prostate Cancer: Updates in Biology, Classification, and Management

Image
New Hope for Aggressive Prostate Cancer: Advances in Understanding and Treating Neuroendocrine Prostate Cancer Revolutionary diagnostic tools and promising new therapies offer renewed hope for patients with treatment-resistant disease What Patients Need to Know For most men with prostate cancer, treatments targeting the androgen receptor (AR) pathway—including hormone therapy and newer drugs like enzalutamide and abiraterone—are highly effective. However, as these treatments have become more successful, doctors have observed an important but concerning phenomenon: some cancers develop resistance by essentially changing their identity. This transformation, called neuroendocrine prostate cancer (NEPC), represents one of the most aggressive forms of the disease. At the recent 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Himisha Beltran from Dana-Farber Cancer Institute presented groundbreaking research that offers new hope for patients facing this challenging ...
Read more